Log in or Sign up for Free to view tailored content for your specialty!
Practice Management News
Healio Rheuminations talked burnout with the Glaucomfleckens, tackled autoimmunity in 2023
Move over, Marc Maron. Step aside, Sharon Says So. Make way for Adam Brown, MD, of the Cleveland Clinic, host of the “Healio Rheuminations” podcast.
Best rheumatology Q&As of 2023 covered Alzheimer’s, lupus in a catatonic patient
In 2023, Healio had questions, the experts had answers.
Log in or Sign up for Free to view tailored content for your specialty!
The next generation of rheum agents: Immunomodulation with neonatal Fc receptor targeting?
Our cover story this month is on the next wave of immune-based therapies for patients with immune-mediated inflammatory conditions — and the prospects are bright.
‘A great step forward’: The next wave of rheum therapies offers ‘tantalizing’ approaches
In rheumatology, the next generation of new therapies always seems to be just out of reach, or perpetually “only a few years” away. However, several novel, and not-so-novel, approaches are giving hope that the future may finally soon arrive.
ACR applauds Congress for dedicating $10 million to arthritis research in defense budget
The American College of Rheumatology applauded Congressional lawmakers for providing a $10 million annual line item for arthritis research in the recently passed $886 billion national defense bill.
Match Day fills 61.5% of pediatric rheumatology fellowship slots, continuing decline
Pediatric rheumatology fellowship programs filled just 61.5% of available slots for 2024 in the National Resident Matching Program, while nearly all adult program slots were filled, according to the American College of Rheumatology.
Sarilumab superior to placebo for achieving sustained remission in polymyalgia rheumatica
Among patients with polymyalgia rheumatica who relapse during glucocorticoid tapering, sarilumab is effective at enabling them achieve sustained remission and lowering cumulative glucocorticoid use, according to data.
‘Tough to say’: Complications, guarded optimism surround Medicare price negotiations
Following HHS’ blockbuster announcement of the first 10 drugs that would be subject to Medicare price negotiations, patients and providers alike have been looking forward to meaningful reductions in their costly treatments.
FDA grants fast track designation for novel myasthenia gravis therapeutic
The FDA has granted fast track designation for KYV-101, an autologous, fully human CD19 chimeric antigen receptor T-cell product candidate, to treat myasthenia gravis.
A ‘hidden practice’: Senior physicians see fewer underrepresented patients
Senior physicians cared for fewer patients in underrepresented racial and ethnic groups as well as those with Medicaid compared with their junior colleagues within the same practice, a study published in JAMA Network Open found.
-
Headline News
VIDEO: Surface attacks in health care will be a ‘source of constant vulnerability’
January 02, 20256 min watch -
Headline News
National Kidney Foundation consensus: Race-free eGFR may optimize decision-making
January 09, 20252 min read -
Headline News
Cannabis use, schizophrenia genetic predisposition both independently raise psychosis risk
January 06, 20252 min read
-
Headline News
VIDEO: Surface attacks in health care will be a ‘source of constant vulnerability’
January 02, 20256 min watch -
Headline News
National Kidney Foundation consensus: Race-free eGFR may optimize decision-making
January 09, 20252 min read -
Headline News
Cannabis use, schizophrenia genetic predisposition both independently raise psychosis risk
January 06, 20252 min read